Heart failure & cardiomyopathies
Baroreflex Activation Therapy in Advanced Heart Failure: A Long-Term Follow-Up
Authors' conclusion
BAT resulted in a substantial reduction in NYHA classification and improvement in LVEF that lasted over long-term follow-up in many patients. NT-proBNP level decreased interim in long-term follow-up.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) who received baroreceptor activation therapy (BAT) at Hannover Medical School, 2014–2023
- Participants
- 23 patients
- Outcome
- Long-term outcome:
- Symptom burden
- Echocardiography
- Laboratory testing
- Follow-up
- Mean 3 ± 2 (max. 7.5) years
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- New York Heart Association (NYHA) class reduced at 1 year
- 12 patients (52%)
- Improvement in left ventricular ejection fraction (LVEF) at 1 year
- 9 ± 9% (P < 0.001)
- Improvement in LVEF at 2 years
- 11 ± 9% (P = 0.005)
- NT-proBNP reduction at 1 year (non-significant)
- 396 ± 1006 pg/mL
- NT-proBNP reduction at 2 years
- 566 ± 651 pg/mL (P = 0.039)
Observational data: associations, not effects.
Further findings
LVEF improvement · 2 years
- LVEF improvement
- 11 ± 9%
- P = 0.005
NT-proBNP reduction · 1 year
- NT-proBNP reduction, non-significant
- 396 ± 1006 pg/mL
NT-proBNP reduction · 2 years
- NT-proBNP reduction, significant
- 566 ± 651 pg/mL
- P = 0.039
Device exchange at recommended replacement time
- Patients with device exchange
- 7
Deaths during observation
- Patients who died
- 4
Safety
| Outcome | Values |
|---|---|
| Complication during BAT implantation | BAT 4% |
Original publication
Baroreflex Activation Therapy in Advanced Heart Failure: A Long-Term Follow-Up. ESC Heart Fail. Published 8 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →